Company profile: Cellca
1.1 - Company Overview
Company description
- Provider of upstream technologies and services for mammalian protein manufacturing, including a proprietary CHO expression platform, rapid cell line development (DNA to research cell bank in ~14 weeks), cGMP cell banking, cell line and product characterization, and cGMP lot release testing aligned with ICH and USP guidelines.
Products and services
- Cell Banking: Delivers integrated creation and testing of cell banks in cGMP-compliant facilities, ensuring rapid release to support upstream mammalian protein manufacturing
- Cell Line Development: Engineers biologics-focused programs that advance from DNA to research cell bank in approximately 14 weeks, concentrating on cell line creation for biologics production
- Cellca CHO Expression Platform: Proprietary host cell and expression vector system engineers efficient mammalian protein production, delivering high-expression technology characterized by efficiency and robustness for upstream bioproduction
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cellca
Bioceros
HQ: The Netherlands
Website
- Description: Provider of biopharmaceutical R&D contract services spanning discovery research to pre-clinical development, including assay development and quantification, molecular and cell biology, and services related to preclinical development of monoclonal antibodies and generation of protein-producing cell lines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bioceros company profile →
Cytel
HQ: United States
Website
- Description: Provider of statistical software and advanced analytics for clinical trial design and execution, offering East and Solara for optimal trial design, Real World Evidence services, Synthetic Control Arms, and Data Monitoring Committees, helping biotech and pharmaceutical companies navigate uncertainty and make evidence-based decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cytel company profile →
BioVectra
HQ: Canada
Website
- Description: Provider of contract development and manufacturing services for intermediates and active pharmaceutical ingredients, with over 40 years' experience serving global pharmaceutical and biotechnology clients. Capabilities span synthetic organic chemistry, microbial fermentation for biologics (e.g., recombinant insulin), synthetic small molecules, highly potent APIs, bioreagents, and pDNA/mRNA production.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioVectra company profile →
Reaction Biology
HQ: United States
Website
- Description: Provider of assay services and protein production for early-stage drug discovery, including biochemical, biophysical, electrophysiological and cell assays for high throughput screening (HTS); kinase and epigenetic assays; recombinant and custom protein production; 2D/3D cell-based assays; in vivo pharmacology (xenograft, immuno-oncology tumor models); and ADME & safety with in vitro safety screening, cardiac safety assessment, and in vivo PK/PD studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reaction Biology company profile →
BTS Research
HQ: United States
Website
- Description: Provider of GLP, non-GLP, and cGMP biological and preclinical research services for pharmaceutical, biopharma, and academic clients, including in vitro clinical pathology, bioanalytical for small molecules and biologics, and cell-based functional assays; in vivo studies using validated disease models (cancer, inflammation, metabolic diseases); pharmacology (PK/PD), toxicology (acute to neurotoxicity), and SARS‑CoV‑2 neutralizing antibody assays in animal models.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BTS Research company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cellca
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cellca
2.2 - Growth funds investing in similar companies to Cellca
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cellca
4.2 - Public trading comparable groups for Cellca
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →